Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
World game at war: why some European nations have threatened a World Cup boycott 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Anthropic Reveals Claude AI Accessed Real Production Systems During Cybersecurity Tests 
Same sparkle, different story: how lab-grown diamonds are transforming the market 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
INDIANAPOLIS and SAN FRANCISCO, April 10, 2018 -- Assembly Biosciences, Inc. (NASDAQ:ASMB), a clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel oral live biotherapeutics for disorders associated with the microbiome, today announced that it plans to host a conference call and live audio webcast on Thursday, April 12, 2018, at 8:00 am ET/2:00 pm CET to review interim results from Phase 1a and 1b studies of ABI-H0731 being featured in a “late-breaker” poster presentation at The International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at assemblybio.com. Alternatively, participants may dial (866) 362-6480 (domestic) or (706) 679-0386 (international) and refer to conference ID 3669097.
The archived webcast will be available on Assembly’s website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Assembly Biosciences
Assembly Biosciences, Inc. is a clinical-stage public biotechnology company developing two innovative platform programs: an HBV program advancing a new class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. Assembly’s HBV program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic HBV. The company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current Good Manufacturing Practices and a patent-pending delivery system, GEMICEL®, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Assembly is developing a robust pipeline of product candidates in multiple disease indications. For more information, visit assemblybio.com.
Contacts
Assembly Biosciences, Inc.
Investors:
Lauren Glaser
(415) 521-3828
[email protected]
